Replies to post #304324 on NorthWest Biotherapeutics Inc (NWBO)

[marzan]

Wow ATLnsider, LL and MB are presenting and it is a Late Breaking Plenary one at SNO on 11/20. Apparently, they are discussing the details of the Phase 3 DcVaxL data at the SNO podium. So, TLD must come before. And DL must come even prior to TLD or DL has already happened. JT announced the TLD of Amarin's Reduce It trial in Sep 2018. Looks like the CEO announcing TLD is the norm. I predict LP release TLD next Saturday. Amarin waited almost a month and a half and let Dr. Bhatt, the PI, present the data in a Cardio conference in November 2018. No wonder 45M shares are sold in the last 3 trading days. Someone knows something! Very interesting weeks ahead!!

[Cclr0007]

Thanks for broadcasting this . I cuts a clear path forward!

[extrooper]

This could be the updated presentation that sets the GBM therapy world a fire & DCVax-L Speculation will be put to rest .

[skitahoe]

This is the right conference at the right time, once the data's been peer reviewed it should be available for everyone to see on the company website. Until that time, we'll learn about it from TLD and anything more that might be presented by the company. This is the conference I've hoped they'd get into for months.

Gary

[CassieW]

THIS IS HUGE!!!!!! Congrats $NWBO longs!
The writing isn’t just on the wall- it’s ALL OVER THE WALL!!!

[flipper44]

That’s it. Let’s get it to patients. Post haste.

[hyperopia]

WOW nice find ATL, thanks for posting. I thought that's where they'd present, but I'm surprised it's out already.

[Hbpainter]

The best news in years! I don't think they'll be presenting results of a failed trial.!

[eagle8]

Thank you ATLnsider for sharing.
Future is bright for us longs.

GLTU

[abeta]

ATL - Thank You.

Friday, November 20, 2020

LTBK-02 - Phase III Clinical Trial to Test the Safety and Efficacy of Autologous Tumor Lysate-Loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma

Learning Objectives:

Upon completion, participant will be able to better understand the impact of dendritic cell-based immunization strategies o the course of disease in glioblastoma patients.

Upon completion, participant will be able to assess whether patients with glioblastoma live longer if treated with dendritic cell-based immunization strategies.

https://www.eventscribe.com/2020/SNO/fsPopup.asp?efp=S0taQ1hBSFkxMTYzNQ&PresentationID=772799&rnd=0.2810788&query=Dcvax&mode=presinfo

[scotty3371]

Where does it say "DCVax-L Phase 3 clinical trial detailed results and analysis will be presented by Drs. Linda Liau & Marnix Bosch at the 2020 Society for Neuro-Oncology (SNO) on 11/20/2020"

??

[H2R]

The finish line is set. SNO Nov. 20, 2020. TLD before then. DL before TLD.

Longs, we are there.

Great find ATLnsider!

Best of luck to Patients, NWBO, and Longs!

[GoodGuyBill]

From SmithOnStocks:


Late Breaking News

It has just been reported that Dr. Linda Liau and Dr. Marnix Bosch will present a paper on the phase 3 results at the Society for Neuro-Oncology on Friday November 20, 2020. See this link.

[antihama]

Oh Boy! Wow and Double Wow! "This is the big one!...You hear that, Elizabeth!"

LTBK-02 - Phase III Clinical Trial to Test the Safety and Efficacy of Autologous Tumor Lysate-Loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma
Friday, November 20, 2020
Live Abstract Presenter(s)
Linda Liau, MD, PhD photo
Linda Liau, MD, PhD

Director, Brain Tumor Program, UCLA David Geffen School of Medicine
University of California Los Angeles

Arbor Pharmaceuticals (Consultant)JW Creagene (Consultant)

Author(s)
MB
Marnix Bosch, MBA, PhD

Northwest Biotherapeutics

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Participants should be aware of the following financial/non-financial relationships:
Linda M. Liau, MD, PhD: Arbor Pharmaceuticals (Consultant)JW Creagene (Consultant)
Marnix Bosch, MBA, PhD: No disclosure data submitted.


Background: Glioblastoma (GBM) is an incurable form of brain cancer with a high mortality rate in which multiple treatment attempts over the past decade have proven unsuccessful at extending survival. Early stage data have suggested that immunization against tumor cell antigens may be effective in GBM. In this Phase 3 study we aimed to assess whether autologous dendritic cells (DCs) loaded with autologous tumor cell lysate, is able to improve survival in these patients.

[Evaluate]

I wonder how the travel experience will be for Marnix Bosch, from the Netherlands to USA and back. Are there currently still any travel restrictions between Europe & USA? Will Dr Bosch need to subject himself to a quarantine period in order to undertake this trip?